The coronavirus outbreak has raised big questions about the supply chain of pharmaceutical ingredients and drugs necessary to supply world markets and run clinical trials. As the industry transitions from a worldwide network of supply chain transit to a mix of local and global production, how has contagion affected the supply chain and where are that chain's weakest links?
We’ll bring together a group of experts to explore what lessons are being learned for the post-pandemic world.
Evan Loh, M.D. is the Chief Executive Officer since June 2019. Prior to that, Dr. Loh served as Chief Operating Officer from January 2017 to June 2019 and as President and Chief Medical Officer from July 2014, in each case until June 2019. He is a member of the Board of Directors since July 2014.
Anne McDonald Pritchett PhD is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA).
Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation.
In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.
Mr. Craig Kennedy is Senior Vice President of Transformation and Supply Chain Management. Craig has a proven track record of driving change and operations improvement at Merck. Craig will enable our transformational efforts focused on Fortify Plant to Patient integrating financial planning, MMD’s Digital strategy, accelerating Merck Production System, Merck for Mothers, Enterprise Resiliency Modernization and Enterprise Risk Management positioning Merck for the long term.
Since joining Merck in 1996, Craig’s Merck experience has broadly encompassed Regional operations management, plant management and direct manufacturing operations, change management functions, SAP implementation, Supply Chain and inventory management, capacity management and materials management.
John DiLoreto is the Executive Director of the Bulk Pharmaceuticals Task Force (BPTF), an industry trade organization representing manufacturers of active pharmaceutical ingredients, intermediates and excipients. The Task Force addresses regulatory and plant operations issues related to current Good Manufacturing Practices compliance.
BPTF establishes sound working relationships with regulators, allied industries and the public and serves as a reliable source for the development and implementation of balanced regulations and industry guidance resources. The Task Force undertakes this advocacy on behalf of its member companies to achieve drug product and drug substance supply chain safety for consumers. BPTF has been a key stakeholder in negotiations with the FDA on the implementation of GDUFA.
Mr. DiLoreto, a Chemical Engineer, founded NanoReg, a professional services firm specializing in regulatory compliance for nanoscale substance manufacturers and management of chemical and pharmaceutical industry trade associations.
John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his previous daily industry coverage at FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard.